consultancyoreo.blogg.se

Surgical resection followed by post-operative radio- and chemotherapies represent the current standard of care, but more than 90% of GBM tumors will return. While the last decades have seen advances in treatment strategies for different types of cancer, glioblastoma remains a major therapeutic challenge, the authors noted. Shah and colleagues reported on the technology, and preclinical results, in a paper titled, “ Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells.” In their report, the authors concluded, “Upon validation, this study will pave the path to clinical testing in Phase I/II study in primary and recurrent GBM patient cohorts.” “In the future, we will be applying this strategy to promptly identify target receptors after one receives a GBM diagnosis, then administer a gel-encapsulated, off-the-shelf, engineered stem cell therapeutic from a pre-made reservoir.”

“This is the first study to our knowledge that identifies target receptors on tumor cells prior to initiating therapy, and using biodegradable, gel-encapsulated, ‘off-the-shelf’ engineered stem cell based therapy after GBM tumor surgery,” said Khalid Shah, PhD, director of the Center for Stem Cell and Translational Immunotherapy (CSTI) and the vice chair of research in the department of neurosurgery at the Brigham and Women’s Hospital, and faculty at Harvard Medical School and Harvard Stem Cell Institute (HSCI). The results of a study, reported in Nature Communications, confirmed that the treatment was effective in preclinical models of GBM, with 100% of mice living for more than 90 days after treatment.

Scientists headed by teams at Brigham and Women’s Hospital and Harvard Medical School have now devised a novel therapeutic strategy for post-surgical treatment of GBMs that uses biogel-encapsulated healthy donor-derived stem cells engineered to attack GBM-specific tumor cells. Glioblastomas (GBMs) are highly aggressive tumors of the brain and spinal cord that are challenging to treat because many cancer therapeutics cannot pass through the blood-brain barrier.